





Prognostic values of sera IL-6/IL-10 and high titration of anti-SSA/Ro and anti-SSB/La autoantibodies in female patients with connective tissue diseases

Nor Effa S. Zulkafli^{1*} , Anisah Abdul Zubir^{2,3}, Balqissiah Baharudin^{2,3}, Chuo Luan Tan^{3,4}, Nurul Aulia Zakaria^{3,4,5}, Ernest Mangantig⁶ 

¹Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang 13200, Malaysia

²Department of Pathology, Hospital Tuanku Fauziah, Kangar 01000, Malaysia

³Ministry of Health Malaysia, Federal Government Administrative Centre, Putrajaya 62590, Malaysia

⁴Department of Internal Medicine, Hospital Sultanah Bahiyah, Alor Setar 05460, Malaysia

⁵Department of Internal Medicine, Sultan Ahmad Shah Medical Centre, International Islamic University of Malaysia, Kuantan 2500, Malaysia

⁶Department of Community Medicine, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang 13200, Malaysia

***Correspondence:** Nor Effa S. Zulkafli, Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, Penang 13200, Malaysia. effa@usm.my

Academic Editor: Jean Amiral, Hyphen BioMed, France

Received: May 16, 2024 **Accepted:** April 2, 2025 **Published:** May 21, 2025

Cite this article: Zulkafli NES, Zubir AA, Baharudin B, Tan CL, Zakaria NA, Mangantig E. Prognostic values of sera IL-6/IL-10 and high titration of anti-SSA/Ro and anti-SSB/La autoantibodies in female patients with connective tissue diseases. *Explor Immunol.* 2025;5:1003197. <https://doi.org/10.37349/ei.2025.1003197>

Abstract

Aim: The high levels of anti-SSA/Ro and anti-SSB/La autoantibodies are closely associated with a group of diseases related to connective tissues, also known as connective tissue diseases (CTD). The current study attested to profile the multifactorial association between interleukin IL-6 and IL-10 in sera from the study cohort to underline its putative prognostic and therapeutic characteristics for future application in CTD.

Methods: The study cohort was recruited from government hospitals and screened for autoantibody using Enzyme Immunoassay (EIA) and Immunofluorescence Assay (IFA) while cytokine levels were measured using ELISA.

Results: Our data showed the mean age of female patients is 38.1 years. Higher mean levels of both cytokines were observed in the first year of disease onset and menopause autoimmune-CTD patients. The mean levels of IL-6 and IL-10 were significantly higher in positive anti-Ro/La compared to the control group ($p < 0.05$). Also, the significant correlation of IL-6 and IL-10 in CTD patients as opposed to healthy control has underlined the putative role of these biologics.

Conclusions: These data suggest the putative manipulation of IL-6 and IL-10 as prognostic and therapeutics molecules in managing CTD, as an alternative to steroid-based medications to control the disease manifestations.



Keywords

IL-6, IL-10, anti-Ro/anti-La, interleukins, cytokine, connective tissue diseases, SLE, rheumatoid arthritis

Introduction

The classification and immune cytokine association

Autoimmune diseases (AIDs) are conditions where immune cells of the host attack its cells and tissues leading to the production of autoantibodies targeting self-proteins [1]. There are more than 80 types of AIDs such as type 1 diabetes (T1D), multiple sclerosis (MS), Sjogren's syndrome (SS), rheumatoid arthritis (RA), graves' disease (GD) and systemic lupus erythematosus (SLE) [1, 2]. AIDs are the third most common disease in the USA after cancer and cardiovascular diseases [3]. The prevalence of AIDs is about 5–8% in the general population predominantly females (78%) and varies according to ethnicity and geographical area [4]. Asian and non-Caucasian patients are more prone to develop severe SLE with poorer outcome [5]. In our multiracial setting, the prevalence of female SLE was 85.9% compared to that of males (14.1%) and the majority of them were Malays followed by Chinese, Indians, and others [6].

Anti-Ro/La autoantibodies and AIDs

The aetiology of AIDs is not entirely elucidated but pieces of evidence are suggesting that the multifactorial pathogenesis of autoimmunity, which includes genetic, and epigenetics regulation may herald changes into the uncontrolled immune responses, leading to destructive reactions of autoantibodies towards self-proteins binding [7, 8]. Autoantibodies are the immunoglobulins reacting against self-molecules or proteins [9]. Due to its high titre and varying subtypes in AIDs, autoantibody detection against cellular components has been utilized as one of the serologic indicators during autoimmune conditions [10, 11]. A nuclear-speckled pattern of cells is commonly found in several AIDs including SLE, SS, scleroderma and mixed connective tissue disease (MCTD), indicating the presence of anti-nuclear antibodies against the nuclear proteins [12]. While the presence of pathogenic autoantibodies is highly specific in organ-specific AIDs such as thyroiditis and T1D, in systemic AIDs like SLE, it is less specific and directed against multiple organs [8]. In SLE and other systemic autoimmune conditions such as subacute cutaneous lupus erythematosus (SCLE), anti-Ro is commonly found autoantibodies while anti-La is mostly found in SS patients [13]. Anti-Ro autoantibodies are usually detected alone in human sera whereas anti-La autoantibodies are often in company with anti-Ro autoantibodies [14]. And because cytokines play a major role in the pathogenesis of AIDs, they may serve as putative biomarkers for local and systemic inflammatory responses [15].

Cytokine roles in AIDs

In most AIDs, the balance between pro- and anti-inflammatory cytokines determines the extent of inflammation. Pro-inflammatory cytokines contribute to the initiation and propagation of autoimmune inflammation, whereas anti-inflammatory cytokines facilitate the regression of inflammation and promote recovery from an acute phase of the disease [16]. A previous study has shown that certain cytokines exhibited pleiotropic effects, which may exert both pro- and anti-inflammatory effects in the same vicinity [17]. Cytokines are secreted by activated immune cells and divided into two subtypes i.e., type 1 and type 2 subtypes. Type 1 cytokines including interferon- γ (IFN- γ) and IL-2 are produced by Th1 cells responsible for mediating cellular responses. On the other hand, type 2 cytokines such as IL-4, IL-5, IL-6, and IL-10 are produced by Th2 cells and non-T cells such as B cells and monocytes mediate humoral responses [18]. Furuzawa-Carballeda and colleagues (2014) [19] showed that patients with primary SS had a higher number of Th17 and Th19 cells and the cytokine imbalance in local glands and peripheral blood contributed to chronic inflammation in SS [17]. It was shown that peripheral primary monocytes from SS patients produced significantly higher IL-6 and BAFF levels than healthy subjects [20]. Besides, abnormal IL-6 expression may contribute to the development of other AIDs such as RA in which, synovial fluid from the joints of active RA patients showed increased IL-6 levels [21].

Role of IL-6 in AIDs

Interleukin-6 (IL-6) is a pleiotropic cytokine executing a diverse number of biological functions, including hematopoiesis, blood vessel permeability, inflammations and immune responses [22]. Given the multifaceted roles of IL-6 in adverse inflammatory reactions, the correlation between IL-6 levels and other disease burdens has been studied over the years. As reported by Trovato and colleagues [23], a positive correlation was observed between free serum IL-6 levels and the age of HIV-positive patients developing the AIDs over time during the disease course, suggesting the interplay of IL-6 in autoimmunity. Recently, Taylor and colleagues (2024) [24] have examined that IL-6 inhibition affects joint inflammation and other comorbidities associated with individuals with RA.

Role of IL-10 in AIDs

On the other hand, IL-10 cytokine is responsible for inhibiting the production of IFN- γ cytokines and regulating chemokine receptor CCR7 [1, 25]. It also triggers B lymphocytes to induce the secretion of autoantibodies or immunoglobulins [26]. Human IL-10 is a homodimer of 37 kDa and each monomer consists of 160 amino acids [27]. In primary SS patients, IL-10 is secreted by T cells mainly at the inflammatory site in salivary glands and by peripheral blood mononuclear cells. IL-10 and IL-6 play a central role in the maturation of plasma cells and activation of immunoglobulin synthesis [28]. A higher level of IL-10 was detected in the serum of primary SS patients compared to the control group [29]. This is associated with high titres of immunoglobulin A (IgA) of RF, anti-Ro, and anti-La specific antibodies corresponding to the severity of lymphocytic infiltration in the salivary gland [17]. In addition, a significant increase in IL-10 was found in the saliva of SS patients compared to that of healthy controls. This was significantly related to the severity of dryness of the mouth and eyes as well as the erythrocyte sedimentation rate [25].

Future use of cytokines in anti-Ro/La autoantibody detections

Therefore, this study was conducted to determine the association between the pleiotropic cytokine of IL-6 and anti-inflammatory IL-10 with multifactorial analyses in female patients with anti-Ro and anti-La autoantibodies among cohort study recruited from government healthcare multicentre. We compared the presence of single positive anti-Ro and double positive anti-Ro/La with multiple factors including demographic, differential diagnosis, medication, disease progression, menopause status and levels of both IL-6/IL-10 in these patients to measure the fundamental relationship. It is hoped that data from the study may widen the potential use of IL-6/IL-10 as target biomarkers for advanced treatment development against AIDs, other than RA [14].

Materials and methods

Patients and control subjects

Sera from patients who attended the rheumatology clinic suspected of connective tissue diseases (CTD) positive were collected from the Microbiology Unit, Pathology Department, Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia. The medical records were retrieved to match the samples for demographic data analysis and criteria sub-stratification. Designated groups were as the following: anti-SSA/Ro as Group 1 ($n = 35$), double positive anti-SSA/Ro-SSB/La as Group 2 ($n = 35$), and negative control sample as Group 3 ($n = 36$). Inclusion criteria include females aged 18 years old until 80 years old, diagnosed with the presence of anti-Ro or anti-La or both regardless of differential diagnosis. Exclusion criteria include males, age group under 18 years old, and hemolyzed samples. Meanwhile, the negative control group was recruited from blood donors attending the blood bank for blood donations from the same facility and the age range was matched with the study group. All consents and experimental protocols were approved by the Medical Research and Ethics Committee (MREC), Kementerian Kesihatan Malaysia (MREC approval number: (6) KKM/NIHSEC/P17-1363) and Human Research and Ethics Committee (JEPPEM), Universiti Sains Malaysia (USM/JEPPEM/17110570).

Status of menopause, medicines taken, differential diagnosis and disease onset

Menopause status and medicines taken were obtained from the medical records unit of the hospitals using the subject datasheet form. The year of disease onset was defined as the time at which an individual was diagnosed.

Immunoassay for CTD screen and extractable nuclear antigen marker

Samples were screened for CTD using an automation Enzyme Immunoassay (EIA), Immunocap100 (Thermo Scientific, USA). Any presence of anti-nuclear antibody (ANA) patterns was confirmed by indirect Immunofluorescence Assay (IFA), MBL (Japan). Speckled IFA pattern was tested for extractable nuclear antigen (ENA) marker specific to anti-Ro and anti-La autoantibodies by EIA using Immunocap100 (Thermo Scientific, USA). Low titration of these autoantibodies may indicate the incidence of autoreactive B and T cell activities. This method is commonly used to confirm the presence of anti-nuclear antibodies associated with CTDs in patient's blood samples. Sera from patients will be incubated on a glass slide covered with a monolayer of malignant human epithelial cell lines. The slides are washed and any bounded autoantibodies to the cell nuclei will be visualized using the detection antibody, conjugated to a fluorescence tag. The slides are ready for viewing using a fluorescence microscope (This slide is performed for staining at a dilution of 1:800 at a magnification of 40×).

Detection of total protein concentration

Micro bicinchoninic acid (BCA) protein assay kit by Thermo Scientific™ (USA) was used to quantify the total protein. Sera samples were diluted at a ratio of 1:1,000 (1 µL sera: 999 µL PBS). Samples were pipetted into the 96-microplate wells in triplicates. 150 µL of working reagent was added to each well and the plate was mixed thoroughly on a plate shaker for 30 seconds and incubated at 37°C for 2 hours. After incubation, the plate was cooled to room temperature and the absorbance was measured at 562 nm on a spectrophotometer (Thermo Scientific). The standard curve was used to determine the protein concentration of each sera sample.

Analysis of cytokine levels

IL-6 and IL-10 were measured using pre-coated ELISA plates against these analytes according to the manufacturer's protocol (Elabscience, China). A standard curve graph was prepared by plotting the average Blank-corrected 450 nm reading for each reference standard versus IL-6/IL-10 concentration in pg/mL. The standard curve was used to determine the IL-6/IL-10 concentration of each sample.

Statistical analysis

Data from experimental analyses were presented as a mean of triplicates with standard error mean (mean \pm SEM) and standard deviation (SD). The data were statistically analysed using IBM SPSS statistics for Windows software (Version 19.0. Armonk, NY: IBM Corp). Analyses for multifactorial between cytokine levels and patients diagnosed with autoimmune-CTD were performed by multiple logistic regression. Pearson correlation test was performed to analyse the relationship between pro- and anti-inflammatory cytokines and anti-Ro, anti-La and anti-Ro/La autoantibodies. Comparison between control and positive groups was tested for significance using the one-way analysis of variance ANOVA test and p value of less than 0.05 ($p < 0.05$) is considered significant.

Results

Demographic distribution of single positive anti-SSA/Ro and double positive anti-SSA/Ro-SSB/La

We first identified the demographic distribution of single anti-Ro and double anti-Ro/La autoantibodies in the cohort study. Samples from patients were analysed for demographic parameters. From the data, the mean age of a female with a single positive anti-Ro and a double positive anti-Ro/La is 38.1 years old (SD \pm 15.01) ($n = 70$). Malay women represented the highest frequency of both single and double positive cases in the region at 72.6%, followed by Chinese at 17.1%, Indian at 7.5%, and other races at 2.8% respectively.

ANA reporting commonly involves two components i.e., quantitative and qualitative of ANA. Table 1 has tabulated the quantitative measurement of ANA using antibody titre. Four titration ratios were used to categorize the level of autoantibodies detection in patient's samples i.e., 1:100, 1:400, 1:800, and > 1:800 dilution titration ratio. It was shown that on 31.4% of samples from single positive anti-Ro, ANA was optimally detected at the lowest titration ratio of 1:100, while 25.7% detected at a titration ratio of 1:800, 22.9% detected at a ratio > 1:800, followed by 20.0% samples detected with ANA at 1:400 titration ratio. Meanwhile, in double positive anti-Ro/La, 37.2% of samples were detected with ANA at the highest dilution titration i.e., > 1:800 titration ratio. This was then followed in 34.3% of samples with ANA detected at a 1:800 ratio, 17.1% of samples detected with ANA at a 1:100 ratio, and followed by 11.4% of samples with ANA detected at a 1:400 titration ratio.

Table 1. Analysis of titration of ANA IFA staining in single positive anti-SSA/Ro (Group 1) and double positive anti-SSA/Ro anti-SSB/La (Group 2)

Titration	Group 1 (n = 35)	Group 2 (n = 35)
	n (%)	n (%)
1:100	11 (31.4)	6 (17.1)
1:400	7 (20.0)	4 (11.4)
1:800	9 (25.7)	12 (34.3)
> 1:800	8 (22.9)	13 (37.2)

ANA: anti-nuclear antibody; IFA: Immunofluorescence Assay

In the cohort study, we analysed the titration of ANA IFA staining in single positive anti-SSA/Ro and double positive anti-SSA/Ro anti-SSB/La for nuclear-speckled pattern detection (Figure 1). A course-speckled pattern is a common indication of autoantibodies to anti-U1RNP and anti-Sm proteins, while a fine-speckled pattern refers to the presence of anti-Ro and anti-La autoantibodies [9].




Figure 1. A representative of an indirect Immunofluorescence Assay (IFA) staining of a patient's serum for antinuclear antibodies (ANA). The green fluorescence indicates the presence of ANA binding to nuclear antigens within the cells. The nuclear-speckled pattern was detected in a sample from the cohort at a dilution of 1:800 at a magnification of 40×. The metaphase cell showed no staining of the condensed chromosomal region, while the figure showed a fine to discrete speckled pattern of the interphase cell in a uniform distribution. The course-speckled pattern is a common indication of autoantibody binding of anti-U1RNP and anti-Sm proteins while the fine pattern represented the anti-Ro and anti-La binding

For any positive ANA, antibody titration needs to be performed to determine the quantification of ANA that has been detected in the samples. In this study, four titration ranges were used to determine the presence of ANA. Up to 31.4% of subjects with single positive anti-SSA/Ro are optimally detected with ANA at the lowest antibody titre while 17.1% with double positive anti-SSA/Ro anti-SSB/La are optimally detected at the same titre. The study cohort showed that most individuals with a single positive anti-SSA/Ro can be detected at lower antibody titre, indicating higher levels of ANA formed during the disease occurrence.

Clinical characteristics of patients in Group 1 and Group 2

Next, we analysed the clinical characteristics of these patients from the same cohort. All patients were stratified into clinical attributes as shown in Table 2. These attributes were analysed to determine the correlation of the factors contributing to the incidence of autoantibody formation. The single-positive anti-Ro autoantibodies (Group 1) and double-positive anti-Ro/La autoantibodies (Group 2) were tabulated in Table 2 with the attributes analysed. Differential diagnosis for individuals with anti-Ro and/or anti-Ro/La autoantibodies includes SLE, SS, MCTD, RA, and other types of AIDs. It was shown that most patients were treated with steroid-based drug therapy to minimize signs and symptoms.

Table 2. Clinical characteristics of patients in Group 1 (single positive) and Group 2 (double positive group)

Variables	Group 1 (n = 29) (%)	Group 2 (n = 25) (%)
Age (year)	40.7 (17.7) ^a	34.0 (27.0, 55.5) ^b
Age group		
Under 25	8 (27.6)	6 (24.0)
26–45	9 (31.0)	11 (44.0)
46 and older	12 (41.4)	8 (32.0)
Disease progression		
≤ 1 year	5 (17.2)	10 (40.0)
2–4 years	7 (24.1)	8 (32.0)
≥ 5 years	6 (20.7)	5 (20.0)
Missing	11 (37.9)	2 (8.0)
Diagnosis		
SLE	4 (13.8)	14 (56.0)
SS	1 (3.4)	2 (8.0)
MCTD	4 (13.8)	1 (4.0)
Other AID	9 (31.0)	6 (24.0)
Others	11 (37.9)	2 (8.0)
Menopause status		
Yes	9 (31.0)	7 (28.0)
No	20 (69.0)	18 (72.0)
Medication		
On steroid	16 (55.2)	22 (88.0)

^a Mean (standard deviation); ^b Median (interquartile range); SLE: systemic lupus erythematosus; SS: Sjogren's syndrome; MCTD: mixed connective tissue disease; AID: autoimmune disease. Data not available: Confirmed diagnosis date from 6 subjects from Group 1 and 10 subjects from Group 2 are not available

Table 2 shows the characteristics of patients in both groups. Group 1 i.e., single positive group consisted of 29 patients with a mean age of 40.7 (SD ± 17.7) years old. The minimum and maximum age were 18 and 80 years old, and the majority (41.4%) were in the age group 46 and older. Most of the patients (82.8%) were of Malay ethnicity. In regard to disease progression, about 24% of the patients have been diagnosed between two to four years. Approximately 37.9% of the sample had missing information on disease onset. The majority of the group were diagnosed as others, followed by 31% with other AIDs, 13.8% with SLE and MCTD, respectively, and 3.4% with SS. Of all patients, only 31% had menopause and 55.2% took steroid medication.

Meanwhile, in double positive group (Group 2), there were 25 patients with a median age of 34 years. The minimum and maximum age of patients in this group were 18 and 69 years old, and the majority (44%) were in the age group 26–45 years. Most of the patients (88%) were of Malay ethnicity. The majority (40%) had the disease less than one year and 56% had a diagnosis of SLE. Only 28% of the patients had menopause and up to 88% were taking steroid medication. In the current study, disease onset is defined as years from symptom onset to diagnosis time. It was recorded that in single positive patients, disease onset commonly occurred within two to four years in 24.1% of the studied cohort. While in double positive patients, disease onset commonly occurred at less than a year in 40.0% of the studied cohort. Interestingly, around 20.7% of single positive and 20.0% of double positive patients were recorded to have their diagnosis after 5 years of disease onset. This may suggest the differences in the degree of disease progression in patients with a single and double autoantibody among the cohort study.

IL-6 and IL-10 sera levels between clinical variables in single positive and double positive autoantibodies and among patients with CTDs

CTDs are one of the most common AIDs in developed countries and is associated with high levels of anti-SSA/Ro and anti-SSB/La autoantibodies [3]. To outline the fundamental correlation between IL-6 and IL-10 levels and formation of these autoantibodies in differential diagnosis of CTD, we measured these cytokines and mapped to clinical characteristics in patients with single positive anti-SSA/Ro and double positive anti-SSA/Ro anti-SSB/La.

Disease onset

Our data showed that both cytokines were highest among patients with single positive anti-Ro who were diagnosed in less than a year (Table 3). Meanwhile, IL-6 was highest in patients with double positive anti-Ro/La who were diagnosed within 4 years. However, there was no significant difference in IL-10 levels in patients with double positive anti-Ro/La regardless of disease onset. It is interesting to note double positive patients diagnosed in less than a year and after 5 years have lower serum IL-6 levels.

Table 3. Analysis between IL-6 and IL-10 cytokine levels and disease onset in single positive anti-SSA/Ro (Group 1) and double positive anti-SSA/Ro anti-SSB/La (Group 2)

Cytokine	Year*	Group 1	Group 2		
		(Mean in pg/mL ± SD)	n (29)	(Mean in pg/mL ± SD)	n (25)
IL-6	≤ 1	(97.5 ± 140.0)	5	(27.5 ± 15.3)	10
	2–4	(38.5 ± 20.0)	7	(121.5 ± 201.6)	8
	≥ 5	(33.9 ± 27.9)	6	(40.2 ± 20.4)	5
	NA	(46.6 ± 50.5)	11	(46.4 ± 10.1)	2
IL-10	≤ 1	(56.5 ± 46.4)	5	(34.5 ± 30.5)	10
	2–4	(37.0 ± 28.5)	7	(33.0 ± 41.4)	8
	≥ 5	(35.5 ± 25.1)	6	(29.4 ± 22.4)	5
	NA	(36.6 ± 32.6)	11	(30.8 ± 27.3)	2

* Year of disease onset; SD: standard deviation; NA: not available. Data not available: History of disease onset for 6 subjects from Group 1 and 10 subjects from Group 2 are not available

Medication for disease management

Next, we measured the association between pro-inflammatory cytokine IL-6 and anti-inflammatory cytokine IL-10 with medication in the study cohort. As shown in Table 4, there was no significant association between cytokine levels and medication prescribed in CTD vs control group ($p > 0.05$). In these patients, high levels of IL-6 have been recorded in the study cohort as opposed to the control group showed 58.76 vs 27.41 pg/mL ($p > 0.05$). On the other hand, IL-10 was recorded to be slightly higher as compared to the control group showed 38.86 pg/mL vs 22.04 pg/mL (p -value > 0.05). However, there was a significant difference in medication between CTD and the control group ($p < 0.001$) (Table 4). Data from medical records showed that 38 of the CTD patients diagnosed were managed with steroid-based therapy

such as corticosteroids and prednisolone. While the 16 subjects were treated with other than steroids. The most frequent steroids used for treatment are prednisolone or methylprednisolone in combination with antimalarial drugs such as hydroxychloroquine (HCQ) or chloroquine (CQ).

Table 4. Analysis of medication associated with the levels of IL-6 and IL-10 cytokines in patients with autoimmune connective tissue diseases (CTD)

Variables	CTD (n = 54) (pg/mL)	Control (n =35) (pg/mL)	Crude OR (95% CI)	p-value ^b	Adjusted OR (95% CI)	p-value ^c
IL-6 ^a	58.76 (103.83) ^a	27.41 (28.93)	1.011 (0.997, 1.026)	0.110	1.005 (0.979, 1.032)	0.693
IL-10 ^a	38.86 (32.19) ^a	22.04 (20.33)	1.011 (0.997, 1.025)	0.133	1.002 (0.972, 1.033)	0.888
Medication Steroid	38	1	0.002 (0.000, 0.021)	< 0.001*	0.002 (0.000, 0.026)	< 0.001*
Non-steroid	16	34	1.00	-	1.00	-

^a Mean (SD); ^b Simple linear regression; ^c Wald statistic (Multiple logistic regression); * Significant value since $p < 0.05$. OR: odds ratio; CI: confidence interval; CTD: connective tissue disease. Data not available: Medication record for 16 subjects of CTD are not available

Menopause status

To correlate the influence of estrogen hormone in autoantibody formation, we measured the cytokine levels among menopause and non-menopause patients in the current cohort as tabulated in [Figure 2](#). [Figure 2](#) showed that the mean levels for both cytokines were high in menopause patients diagnosed at a very early stage i.e., within a year as compared to non-menopause patients with the same disease onset. Interestingly, IL-6 continued to spike in menopause patients diagnosed within 2 to 4 years compared to non-menopausal patients of the same onset (138.3 ± 250.7 vs 55.0 ± 65.1) ([Figure 2a](#)). Meanwhile, IL-10 was recorded to reduce in the same group of patients (35.5 ± 34.2) ([Figure 2b](#)) and gradually increased in menopause patients who were diagnosed for 5 years and more (46.6 ± 23.5).

Correlation between IL-6 and IL-10 cytokine levels and anti-SSA/Ro and anti-SSB/La autoantibodies

The correlation of IL-6 and IL-10 with Group 1 (single positive anti-Ro) and Group 2 (double positive anti-Ro/La) is tabulated in [Table 5](#). From the data, it was indicated that IL-6 was significantly associated with both Group 1 and Group 2 with p -value of 0.045 and 0.023 respectively. On the other hand, current findings showed that IL-10 was significantly associated with Group 1 only ($p < 0.05$) while not significantly correlated with Group 2 ($p > 0.05$).

Table 5. Correlation of IL-6 and IL-10 with anti-Ro and anti-La autoantibodies in single positive anti-SSA/Ro (Group 1) and double positive anti-SSA/Ro anti-SSB/La (Group 2)

Groups	IL-6		IL-10	
	<i>r</i>	<i>p</i> -value	<i>r</i>	<i>p</i> -value
Group 1 (n = 35)	-0.195	0.045*	-0.327	0.001*
Group 2 (n = 35)	-0.220	0.023*	-0.120	0.219

* Significant value since $p < 0.05$

Mean concentration between IL-6 and IL-10 and high titration of anti-SSA/Ro and anti-SSB/La autoantibodies in the cohort study

Lastly, we measured the mean concentration of these cytokines in Group 1 and Group 2 versus control healthy donor ([Figure 3](#)). The mean levels of IL-6 and IL-10 in Group 1 and Group 2 were significantly higher than the healthy controls ($p < 0.05$). The mean levels of IL-6 in Group 1 were (59.71 ± 13.75 pg/mL), while Group 2 were (70.56 ± 19.54 pg/mL) as compared to healthy control (20.48 ± 2.53 pg/mL). Meanwhile, the mean levels of IL-10 in Group 1 were (45.52 ± 7.287 pg/mL) and Group 2 were (32.96 ± 4.79 pg/mL) and healthy controls were (17.09 ± 2.01 pg/mL). Based on the ANOVA test, the differences in mean levels obtained among cohort study were statistically significant ($p < 0.05$).




Figure 2. Mean in pg/mL of (a) IL-6 and (b) IL-10 cytokines in patients with autoimmune-CTD at different disease onset versus menopause status. The high mean levels of IL-6 and IL-10 are significantly observed on the first year of disease onset and in menopause autoimmune-CTD patients. Patients who haven't reached menopause are shown to have low levels of IL-6 compared to menopausal patients. Interestingly, the higher mean IL-10 levels are observed in menopause patients on their first year of disease onset while reduced in menopause patients who suffer longer than that. In contrast, those who have not menopause significantly reduced their expression regardless of disease onset. Error bar represents the standard error mean (SEM)




Figure 3. Mean concentration of IL-6 and IL-10 in female positive anti-Ro (Group 1) or positive anti-Ro and La (Group 2) versus negative control (healthy donors) (Group 3). ANOVA test; * Indicate significance level $p < 0.05$ as compared to control group. Error bar represents the standard error mean (SEM)

Discussion

Our work was conducted to attest to the significant association between pro- and anti-inflammatory cytokines, IL-6 and IL-10 respectively in patients with single anti-Ro and double anti-Ro/La autoantibodies from cohort study. The cohort was selected from subjects diagnosed with CTDs at different disease onset. We analyzed factors associated with both cytokines to underline the important role of these cytokines in either the development of autoantibodies, disease progression or manifestations.

Population-based analysis showed that race distribution in the studied region may affect the incidence frequency as compared to other races, with a mean age of 38.1 years old. The influence of genetic or race factors on the frequency of autoantibodies has been observed in a few studies [5, 10, 27]. It was demonstrated that Hispanic, African American and Asian individuals are two to three times more prone to develop SLE when compared to Caucasians [5]. Plus, ANA prevalence in the United States population was higher in African Americans compared to Caucasians [10]. The average age of Caucasian SLE patients was 38.6 years old with females predominant [30]. A previous study showed that autoimmune CTD is observed mostly in women of their forties concomitant with the changes in hormonal levels [31]. Meanwhile, analysis of the medical history showed that approximately 97.4% of patients in the study cohort were managed with steroid-based therapy. The common types include prednisolone or methylprednisolone, in combination with antimalarial drugs of HCQ. According to Low and colleagues (2021) [32], treatments for non-communicable diseases may require a long-term duration of prescribed drugs, therefore accessibility and affordability remain the key factors for service providers. In 2019, Park and colleagues [33] reported that HCQ effectively alleviates autoimmunity via Nurr1 receptors. The safety of HCQ has been systematically reviewed by Ruiz-Irastorza and colleagues [34] who reported that HQ prescription displays a wide spectrum of benefits among prescribed patients. The use of HCQ as an off-label treatment option in treating COVID-19 patients has been considered recently [35, 36].

Globally, the average menopausal age is 51 years old while the mean menopausal age among the study population is (49.9 ± 4.27 years old) [37]. To outline the interrelationship between cytokines and disease progression, we further analysed the levels of IL-6 and IL-10 with menopause status among the study cohort. As shown in Figure 2, the current findings showed that both cytokines increased among menopause patients in the early stage of disease development as compared to non-menopause patients. IL-6 continued to spike as the disease progressed along the four-year course. Interestingly, IL-6 levels reduced dramatically as menopause patients progressed into the fifth year of disease onset, with IL-10 remaining low over time. The current findings may suggest the influence of estrogen and progesterone on IL-6/IL-10 cytokine production in patients with positive anti-Ro/La antibodies. Based on current data, it was suggested that reduced estrogen levels exposed women to developing anti-Ro/La autoantibodies which directly correspond to increased risk of developing AIDs. This finding was partially in line with a previous study that reported post-menopausal women are producing higher IL-6 levels following mental stress than men thus providing clinical implications related to inflammatory conditions such as RA and asthma [38].

In addition, the intracellular ERβ expression is significantly lower in CD4+ and CD8+ T cells from female patients with active SLE disease as compared to healthy donors and patients with low active disease [39]. The clinical expression of SLE is mainly associated with sex, independently of age [40]. Younger women have more typical features of SLE such as malar rash, Raynaud's phenomenon and the presence of anti-Ro/La autoantibodies whereas older women (> 55 years old) mainly presented with discoid lesions and serositis [40]. It was suggested that low expression of the anti-inflammatory effect of ERβ and high serum levels of anti-ERα antibodies are possibly contributing to SLE pathogenesis in female SLE patients [41]. Notably, ERs have been demonstrated in various immune cells involving T and B lymphocyte subsets as well as peripheral NK cells [42]. IL-6 expression is significantly decreased upon stimulation of TLRs (7 and 9) in "KIKO" mice (ERα DNA-binding mutant) compared to wild-type mice. These data showed that TLR-induced cytokines are modulated by ERα and require binding to estrogen response elements for optimal inflammatory response. ERα may bind to transcription factors such as NFκB to regulate transcription of IL-6 cytokine production and cell survival [43].

Our study showed that IL-6 was significantly correlated with both single-positive anti-Ro and double-positive anti-Ro/La autoantibodies groups. This is in agreement with a previous study that reported a higher synthesis of IL-6 from monocytes of idiopathic inflammatory myopathies (IIM) patients, which is highly associated with anti-Ro52 autoantibodies [12, 44, 45]. The role of IL-6 at the early stage of disease development, providing putative manipulation towards prognosis and diagnosis of disease progression. It has been demonstrated that pro-inflammatory IL-6 is involved in the autocrine route which maintains B cell hyperactivity, which leads to autoantibody over-production, and its co-stimulatory factors such as TLR-4, IL-1, and IFN resulting in an increased autoantibody production [45]. In addition, the overexpression of IL-6 superfamily receptor molecule glycoprotein (Gp) 130 on B cells of SLE patients in comparison with healthy control subjects indicated the definitive role of IL-6 on connective tissue disease progression [46]. This protein serves as signal transduction subunits for all IL-6-related cytokines thus contributing to the activation of plasma cells and subsequently antibody overproduction.

Our current study on IL-10 showed that it was significantly correlated only in patients with anti-Ro autoantibodies and is in agreement with a report from Mozo and colleagues (2014) [47] that positive SLE patients have significantly higher serum levels of IL-10 than their negative control. The study has shown that the presence of anti-Ro in anti-RibP-positive SLE patients is found to be related to an increase in IL-10 and IFN α levels in sera [47]. IL-10 is a potent growth and differentiation factor for B lymphocyte proliferation and activation via their antigen receptor or CD40 to secrete large amounts of IgG, IgA, and IgM antibodies [48]. There is a significant association between IL-10 imbalance in patients with anti-Ro52 autoantibodies [49] and the hypermethylation of the *IL-10* gene is responsible for the low mRNA expression in Bechet's disease [50], which may suggest that hyperproduction of IL-10 is associated with the formation of autoantibodies.

In the current study, the mean levels of these cytokines also indicated significant differences among cohort study. We have found that both cytokines were significantly higher in patients as compared to healthy controls. IL-6 was found to be higher than IL-10 in patients with double positive anti-Ro/La autoantibodies, as compared to single anti-Ro autoantibodies patients. Previous reports on serum levels of circulating IL-6 showed that IL-6 is significantly higher in SLE patients (40.66 ± 22.8 pg/mL) compared to healthy control (2.32 ± 3.41 pg/mL) of the Eastern Saudi Arabia region, lupus nephritis vs lupus non-nephritis and in SLE patients in India [51, 52]. Interestingly, the significant correlation of IL-6 with the development of Hashimoto's thyroiditis among HIV patients over a period may indicate that IL-6 is pivotal for the incidence of autoantibody formation [23].

In addition, our results were also in line with a previous study that the mean serum IL-10 levels were significantly higher in SLE Egyptian patients and correlated with the SLEDAI scores ($p = 0.016$) [53]. Interestingly, current data reported that IL-10 levels were higher in single anti-Ro autoantibodies than double positive anti-Ro/La autoantibodies, and vice versa for IL-6 sera levels. This may indicate further investigation of the pathogenesis of this differential diagnosis is needed. Persistence inflammation promotes a detrimental role of IL-6, contributing to adverse immune reactions, eventually altering the immune response towards self-proteins. In turn, negative feedback from IL-10 begins to emerge at the beginning of disease progression, as reported by the current study. As the disease progresses due to overwhelming and altered immune response by IL-6 in patients with anti-Ro/La autoantibodies, IL-10 levels are gradually decreased among cohort study. This may be due to the altered epigenetic expression of T-regulatory cells in patients, because of systemic inflammatory response by IL-6. As a result, increased expression of IL-6 during persistent inflammation will induce T-regulatory cell migration away from inflammatory sites, reducing the inhibitory capacity of these cells [54].

In conclusion, it is interesting to note that the differential expression of both cytokines may pave the way for developing biological therapy in AIDs. Current data suggest the possible IL-6 inhibitors/IL-10 stimulants tandem may provide beneficial advancement for the implementation of a treat-to-target strategy in treating AIDs. Overall, our current study may provide additional evidence to the literature on the putative roles of IL-6/IL-10 tandem as biomarkers in autoimmune-associated diseases. Screening and

development of small molecules for IL-6 inhibitors and IL-10 stimulants for therapeutic purposes may be put forward for the next step in validating the potential biological therapy of these cytokines for autoimmune CTD patients, other than the established treatment for RA.

Abbreviations

AIDs: autoimmune diseases

ANA: anti-nuclear antibody

CQ: chloroquine

CTD: connective tissue diseases

EIA: Enzyme Immunoassay

HCQ: hydroxychloroquine

IFA: Immunofluorescence Assay

IFN- γ : interferon- γ

IgA: immunoglobulin A

MCTD: mixed connective tissue disease

MS: multiple sclerosis

RA: rheumatoid arthritis

SLE: systemic lupus erythematosus

SS: Sjogren's syndrome

T1D: type 1 diabetes

Declarations

Acknowledgments

Special thanks to the Ministry of Health for their support and approval. Thanks to the Microbiology Unit, Pathology Department Hospital Putrajaya and Hospital Tuanku Fauziah for sample collections. Special thanks to Mrs. Sangitha, Mr Faizal, and Mrs Atifah from Hospital Putrajaya and Madam Nor Suhaila from Hospital Tuanku Fauziah for their assistance throughout the project.

Author contributions

NESZ: Investigation, Methodology, Data curation, Formal analysis, Writing—original draft, Writing—review & editing. AAZ: Investigation, Methodology, Data curation, Formal analysis, Resources. BB, CLT, and NAZ: Project administration, Resources. EM: Data curation, Formal analysis.

Conflicts of interest

All authors declared no conflict of interest.

Ethical approval

All experimental protocols were approved by the Medical Research and Ethics Committee (MREC), Kementerian Kesihatan Malaysia (MREC approval number: (6) KKM/NIHSEC/P17-1363) and Human Research and Ethics Committee (JEPeM), Universiti Sains Malaysia (USM/JEPeM/17110570).

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Consent for publication has been obtained together with ethical approval of the study from MOH (MREC No: (6) KKM/NIHSEC/P17-1363) and USM JEPEM (USM/JEPEM/17110570).

Availability of data and materials

Data concerning the participants are not publicly available due to ethical restrictions. Requests for accessing the datasets should be directed to [Nor Effa S. Zulkafli, effa@usm.my].

Funding

This study was funded by the Fundamental Research Grant Scheme (FRGS), Ministry of Higher Education of Malaysia [FRGS/1/2019/SKK08/USM/03/14]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

© The Author(s) 2025.

Publisher's note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

1. Abbas AK, Lichtman AH, Pillai S. Basic immunology: functions and disorders of the immune system. 4th ed. India: Elsevier; 2016.
2. Gough SCL, Simmonds MJ. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action. *Curr Genomics*. 2007;8:453–65. [DOI] [PubMed] [PMC]
3. National Institute of Health. National Institutes of Health Autoimmune Disease Coordinating Committee Report. 2002. Bethesda (MD): The Institutes; 2002.
4. Wang L, Wang F, Gershwin ME. Human autoimmune diseases: a comprehensive update. *J Intern Med*. 2015;278:369–95. [DOI] [PubMed]
5. Crosslin KL, Wiginton KL. The impact of race and ethnicity on disease severity in systemic lupus erythematosus. *Ethn Dis*. 2009;19:301–7. [PubMed]
6. Shaharir SS, Kadir WDA, Nordin F, Bakar FA, Ting MWH, Jamil A, et al. Systemic lupus erythematosus among male patients in Malaysia: how are we different from other geographical regions? *Lupus*. 2019; 28:137–44. [DOI] [PubMed]
7. Elkon K, Casali P. Nature and functions of autoantibodies. *Nat Clin Pract Rheumatol*. 2008;4:491–8. [DOI] [PubMed] [PMC]
8. Effa SZN, Phang SJ, Ahmad HF. Autoimmune Diseases and Gut Symbionts: The Unpopular Liaison. *Mal J Med Health Sci*. 2019;15:165–72.
9. Gershwin ME, Meroni PL, Shoenfeld Y. Autoantibodies. Elsevier; 2002. [DOI]
10. Satoh M, Chan EKL, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. *Arthritis Rheum*. 2012;64:2319–27. [DOI] [PubMed] [PMC]
11. Brandt JE, Priori R, Valesini G, Fairweather D. Sex differences in Sjögren's syndrome: a comprehensive review of immune mechanisms. *Biol Sex Differ*. 2015;6:19. [DOI] [PubMed] [PMC]
12. Gómez-Martín D, Galindo-Feria AS, Barrera-Vargas A, Merayo-Chalico J, Juárez-Vega G, Torres-Ruiz J, et al. Ro52/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies. *Clin Exp Immunol*. 2017;188:154–62. [DOI] [PubMed] [PMC]

13. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. *Autoimmunity*. 2005;38:55–63. [\[DOI\]](#) [\[PubMed\]](#)
14. Gottenberg J, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, et al. In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. *Arthritis Rheum*. 2003;48:2240–5. [\[DOI\]](#) [\[PubMed\]](#)
15. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. *Lancet*. 2007;370:1861–74. [\[DOI\]](#) [\[PubMed\]](#)
16. Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. *J Interferon Cytokine Res*. 2011;31:695–703. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
17. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. *Oral Dis*. 2009;15:519–26. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
18. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. *Clin Microbiol Rev*. 1996;9:532–62. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
19. Furuzawa-Carballeda J, Sánchez-Guerrero J, Betanzos JL, Enriquez AB, Avila-Casado C, Llorente L, et al. Differential cytokine expression and regulatory cells in patients with primary and secondary Sjögren's syndrome. *Scand J Immunol*. 2014;80:432–40. [\[DOI\]](#) [\[PubMed\]](#)
20. Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. *Arthritis Res Ther*. 2011;13:R170. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
21. Kishimoto T. The biology of interleukin-6. *Blood*. 1989;74:1–10. [\[PubMed\]](#)
22. Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. *Front Immunol*. 2023;14:1255533. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
23. Trovato M, Ruggeri RM, Sciacchitano S, Vicchio TM, Picerno I, Pellicanò G, et al. Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up. *Immunobiology*. 2018;223:264–8. [\[DOI\]](#) [\[PubMed\]](#)
24. Taylor PC, Feist E, Pope JE, Nash P, Sibilia J, Caporali R, et al. What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? *Ther Adv Musculoskelet Dis*. 2024;16:1759720X241283340. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
25. Bertorello R, Cordone MP, Contini P, Rossi P, Indiveri F, Puppo F, et al. Increased levels of interleukin-10 in saliva of Sjögren's syndrome patients. Correlation with disease activity. *Clin Exp Med*. 2004;4:148–51. [\[DOI\]](#) [\[PubMed\]](#)
26. Willeke P, Gaubitz M, Schotte H, Becker H, Domschke W, Schlüter B. The role of interleukin-10 promoter polymorphisms in primary Sjögren's syndrome. *Scand J Rheumatol*. 2008;37:293–9. [\[DOI\]](#) [\[PubMed\]](#)
27. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach. *Pharmacol Rev*. 2003;55:241–69. [\[DOI\]](#) [\[PubMed\]](#)
28. Anaya JM, Correa PA, Herrera M, Eskdale J, Gallagher G. Interleukin 10 (IL-10) influences autoimmune response in primary Sjögren's syndrome and is linked to IL-10 gene polymorphism. *J Rheumatol*. 2002;29:1874–6. [\[PubMed\]](#)
29. Garcíá-Carrasco M, Font J, Filella X, Cervera R, Ramos-Casals M, Sisó A, et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. *Clin Exp Rheumatol*. 2001;19:411–5. [\[PubMed\]](#)
30. McCarthy EM, Smith S, Lee RZ, Cunnane G, Doran MF, Donnelly S, et al. The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients. *Rheumatology (Oxford)*. 2014;53:1586–94. [\[DOI\]](#) [\[PubMed\]](#)
31. Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? *Arthritis Res Ther*. 2009;11:252. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)

32. Low LL, Rahim FIAB, Hamzah NAR, Ismail MS. Process evaluation of enhancing primary health care for non-communicable disease management in Malaysia: Uncovering the fidelity & feasibility elements. *PLoS One*. 2021;16:e0245125. [DOI] [PubMed] [PMC]
33. Park T, Jang Y, Kim W, Shin J, Toh HT, Kim C, et al. Chloroquine modulates inflammatory autoimmune responses through Nurr1 in autoimmune diseases. *Sci Rep*. 2019;9:15559. [DOI] [PubMed] [PMC]
34. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis*. 2010;69:20–8. [DOI] [PubMed]
35. Gevers S, Kwa MSG, Wijnans E, van Nieuwkoop C. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19. *Clin Microbiol Infect*. 2020;26:1276–7. [DOI] [PubMed] [PMC]
36. Mohana A, Sulaiman T, Mahmoud N, Hassanein M, Alfaifi A, Alenazi E, et al. Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. *Int J Infect Dis*. 2021;102:110–4. [DOI] [PubMed] [PMC]
37. Abdullah B, Moize B, Ismail BA, Zamri M, Nasir NFM. Prevalence of menopausal symptoms, its effect to quality of life among Malaysian women and their treatment seeking behaviour. *Med J Malaysia*. 2017;72:94–9. [PubMed]
38. Endrighi R, Hamer M, Steptoe A. Post-menopausal Women Exhibit Greater Interleukin-6 Responses to Mental Stress Than Older Men. *Ann Behav Med*. 2016;50:564–71. [DOI] [PubMed] [PMC]
39. Maselli A, Conti F, Alessandri C, Colasanti T, Barbati C, Vomero M, et al. Low expression of estrogen receptor β in T lymphocytes and high serum levels of anti-estrogen receptor α antibodies impact disease activity in female patients with systemic lupus erythematosus. *Biol Sex Differ*. 2016;7:3. [DOI] [PubMed] [PMC]
40. Voulgari PV, Katsimbri P, Alamanos Y, Drosos AA. Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. *Lupus*. 2002;11:722–9. [DOI] [PubMed]
41. Mohammad I, Starskaia I, Nagy T, Guo J, Yarkin E, Väänänen K, et al. Estrogen receptor α contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation. *Sci Signal*. 2018;11:eaap9415. [DOI] [PubMed]
42. Pierdominici M, Ortona E. Estrogen impact on autoimmunity onset and progression: the paradigm of systemic lupus erythematosus. *Int Trends Immun*. 2013;1:24–34.
43. Cunningham MA, Wirth JR, Naga O, Eudaly J, Gilkeson GS. Estrogen Receptor Alpha Binding to ERE is Required for Full Tlr7- and Tlr9-Induced Inflammation. *SOJ Immunol*. 2014;2:7. [DOI] [PubMed] [PMC]
44. Kawaguchi Y. Contribution of interleukin-6 to the pathogenesis of systemicsclerosis. *J Scleroderma Relat Disord*. 2017;2:S6–12. [DOI]
45. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. *Ann Rheum Dis*. 2000;59:243–51. [DOI] [PubMed] [PMC]
46. Torre MDL, Urrea JM, Blanco J. Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity? *Lupus*. 2009;18:216–22. [DOI] [PubMed]
47. Mozo L, López P, Caminal-Montero L, Rodríguez-Carrio J, Suárez A. Anti-ribosomal P antibodies are associated with elevated circulating IFN α and IL-10 levels in systemic lupus erythematosus patients. *Lupus*. 2014;23:1477–85. [DOI] [PubMed]
48. Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. *Proc Natl Acad Sci U S A*. 1992;89:1890–3. [DOI] [PubMed] [PMC]

49. Hassan AB, Gunnarsson I, Karlsson G, Klareskog L, Forslid J, Lundberg IE. Longitudinal study of interleukin-10, tumor necrosis factor-alpha, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease. *Scand J Rheumatol*. 2001;30:282–9. [DOI] [PubMed]
50. Alipour S, Nouri M, Khabbazi A, Samadi N, Babaloo Z, Abolhasani S, et al. Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Behçet's disease. *J Cell Biochem*. 2018;119: 6614–22. [DOI] [PubMed]
51. Shaheen DAH, Habib HM, Marie MA. Interleukin-6: a proinflammatory role in nephritis in patients with systemic lupus erythematosus. *Int J Genet Genomics*. 2015;3:53–8. [DOI]
52. Umare V, Pradhan V, Nadkar M, Rajadhyaksha A, Patwardhan M, Ghosh KK, et al. Effect of proinflammatory cytokines (IL-6, TNF- α , and IL-1 β) on clinical manifestations in Indian SLE patients. *Mediators Inflamm*. 2014;2014:385297. [DOI] [PubMed] [PMC]
53. Abd Elazeem MI, Mohammed RA, Abdallah NH. Correlation of serum interleukin- 10 levels with disease activity and severity in systemic lupus erythematosus. *Egypt Rheumatol Rehabil*. 2018;45: 25–33. [DOI]
54. He S, Xue M, Cai G. IL-6 alters migration capacity of CD4⁺Foxp3⁺ regulatory T cells in systemic lupus erythematosus. *Scand J Immunol*. 2021;94:e13099. [DOI] [PubMed]